Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer ORIGINAL ARTICLE ONLINE FIRST Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob, MD; Alicia L. Danforth, MA; Gurpreet S. Chopra, MD; Marycie Hagerty, RN, BSN, MA; Charles R. McKay, MD; Adam L. Halberstadt, PhD; George R. Greer, MD Context: Researchers conducted extensive investiga- of Mood States, and State-Trait Anxiety Inventory were tions of hallucinogens in the 1950s and 1960s. By the early collected unblinded for 6 months after treatment. 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexam- Results: Safe physiological and psychological re- ines a potentially promising clinical application of hal- sponses were documented during treatment sessions. lucinogens in the treatment of anxiety reactive to ad- There were no clinically significant adverse events with vanced-stage cancer. psilocybin. The State-Trait Anxiety Inventory trait anxi- ety subscale demonstrated a significant reduction in anxi- Objective: To explore the safety and efficacy of psilo- ety at 1 and 3 months after treatment. The Beck Depres- cybin in patients with advanced-stage cancer and reac- sion Inventory revealed an improvement of mood that tive anxiety. reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Loading next page...
 
/lp/american-medical-association/pilot-study-of-psilocybin-treatment-for-anxiety-in-patients-with-UvVqm0ICSK
Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/archgenpsychiatry.2010.116
pmid
20819978
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE ONLINE FIRST Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob, MD; Alicia L. Danforth, MA; Gurpreet S. Chopra, MD; Marycie Hagerty, RN, BSN, MA; Charles R. McKay, MD; Adam L. Halberstadt, PhD; George R. Greer, MD Context: Researchers conducted extensive investiga- of Mood States, and State-Trait Anxiety Inventory were tions of hallucinogens in the 1950s and 1960s. By the early collected unblinded for 6 months after treatment. 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexam- Results: Safe physiological and psychological re- ines a potentially promising clinical application of hal- sponses were documented during treatment sessions. lucinogens in the treatment of anxiety reactive to ad- There were no clinically significant adverse events with vanced-stage cancer. psilocybin. The State-Trait Anxiety Inventory trait anxi- ety subscale demonstrated a significant reduction in anxi- Objective: To explore the safety and efficacy of psilo- ety at 1 and 3 months after treatment. The Beck Depres- cybin in patients with advanced-stage cancer and reac- sion Inventory revealed an improvement of mood that tive anxiety. reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with

Journal

JAMA PsychiatryAmerican Medical Association

Published: Jan 1, 2011

References